Global Next Generation Sequencing (NGS) Market – Industry Trends and Forecast to 2026

  • Medical Devices
  • Upcoming Report
  • Sep 2019
  • Global
  • 350 Pages
  • No of Tables: 50
  • No of Figures: 250

Global Next Generation Sequencing (NGS) Market By Product & Service (Pre-Sequencing Products & Services, NGS Consumables, Platforms, & Services for Platforms, Sequencing Services, NGS Data Analysis, Storage, and Management), Technology (Sequencing By Synthesis, Ion Semiconductor Sequencing, Single-Molecule Real-Time Sequencing, Nanopore Sequencing, Other Sequencing Technologies), Application (Diagnostics, Drug Discovery, Agricultural & Animal Research, Other Applications), End User (Academic Institutes & Research Centers, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Other End Users), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) – Industry Trends and Forecast to 2026

Market Analysis: Global Next Generation Sequencing (NGS) Market

Global next generation sequencing (NGS) market is registering a healthy CAGR of 19.60  in the forecast period of 2019-2026. This rise in the market can be attributed to the continuous advancement in NGS technology and upsurge in applications of NGS.

Market Definition: Global Next Generation Sequencing (NGS) Market

NGS means next-generation sequencing; it is also known as massively parallel sequencing technology. NGS allows researchers to research on various applications including speed, scalability, and ultra-high throughput and also study biological systems at a next level. NGS allows researchers to rapidly sequence whole genomes.

Market Drivers

  • Continuous technological advancement in NGS platform is driving the market growth
  • Reducing price of NGS installation is another factor helping in market growth
  • Proper reimbursement and improving regulatory scenario are flourishing the market growth
  • Upsurge in applications of next generation sequencing drives the growth of the market

Market Restraints

  • Less number of skilled personnel hinders the market growth
  • Rising concern about standardization of NGS based diagnostics hampers the market growth
  • Legal and ethical restrictions will act as market restraints

Segmentation: Global Next Generation Sequencing (NGS) Market

By Product & Service

  • Pre-Sequencing Products & Services

    • Sample Preparation

  • NGS Consumables, Platforms, & Services for Platforms

    • NGS Consumables
    • NGS Platforms
    • Services for NGS Platforms

  • Sequencing Services

    • Exome & Targeted Re-Sequencing and Custom Panels
    • RNA-Seq
    • Whole-Genome Sequencing & De Novo Sequencing
    • Other Sequencing Services

  • NGS Data Analysis, Storage, and Management (Bioinformatics)

    • NGS Data Analysis Software & Workbenches
    • NGS Data Analysis Services
    • NGS Storage, Management, and Cloud Computing Solutions

By Technology

  • Sequencing By Synthesis
  • Ion Semiconductor Sequencing
  • Single-Molecule Real-Time Sequencing
  • Nanopore Sequencing
  • Other Sequencing Technologies

By Application

  • Diagnostics

    • Cancer Diagnostics
    • Infectious Disease Diagnostics
    • Reproductive Health Diagnostics
    • Other Diagnostic Applications

  • Drug Discovery
  • Agricultural & Animal Research
  • Other Applications

By End User

  • Academic Institutes & Research Centers
  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Other End Users

By Geography

  • North America

    • U.S.
    • Canada
    • Mexico

  • Europe

    • Germany
    • Italy
    • U.K.
    • France
    • Spain
    • Netherlands
    • Belgium
    • Switzerland
    • Turkey
    • Russia
    • Rest of Europe

  • Asia-Pacific

    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Singapore
    • Malaysia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of Asia-Pacific

  • South America

    • Brazil
    • Rest of South America

  • Middle East and Africa

    • South Africa
    • Rest of Middle East & Africa

Key Developments in the Market:

  • In July 2019, Biodesix, Inc. and Thermo Fisher Scientific have entered into an agreement to provide next-generation sequencing assay for blood-based companion diagnostic solutions in cancer. It is yet to be approved by Food and Drug Administration of the U.S. This agreement will help cancer patient by focusing on NGS-based solution.
  • In June 2019, Agendia declared the open access study validating use of MammaPrint and BluePrint molecular diagnostics using next-generation sequencing technology for targeted RNA.  This will help to understand the complexities of early stage breast cancer and treatment strategies. 

Competitive Analysis:

Global next generation sequencing (NGS) market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of next generation sequencing (NGS) market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Competitors:

Few of the major market competitors currently working in the global next generation sequencing (NGS) market are Illumina, Inc., BGI, Eurofins Scientific, PerkinElmer Inc., Macrogen Inc., DNA Link, Inc., Genotypic Technology Pvt Ltd, WuXi AppTec, GENEWIZ, Takara Bio Inc., SciGenom Labs Pvt. Ltd, Theragen Etex Co., Ltd., LGC Biosearch Technologies, Oxford Gene Technology, Sysmex Inostics, Zymo Research, Source BioScience, Novogene Corporation, among others.

Research Methodology: Global Next Generation Sequencing (NGS) Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report

  • Current and future of global next generation sequencing (NGS) market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)


SKU-

Please fill in the below form for detailed List of Table

Please fill in the below form for detailed List of Figure

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19